Company Intelligence

Isomorphic Labs

Alphabet AI-first drug design company

In this profile

Quick Facts

Executive Summary

Isomorphic Labs is an Alphabet company focused on AI-first drug design. Official communications describe applying machine learning advances—including protein structure modeling lineages from DeepMind research—to therapeutic discovery.Only official Isomorphic Labs sources are used here.

Why It Matters

Isomorphic Labs connects DeepMind-era protein modeling progress to commercial drug design under Alphabet.

Connected Reports

Connected Insights

Industries

Technologies

Introduction

Isomorphic Labs is an Alphabet company focused on AI-first drug design. Official communications describe applying machine learning advances—including protein structure modeling lineages from DeepMind research—to therapeutic discovery.

Only official Isomorphic Labs sources are used here.

What the company does

AI-first drug design company applying advances in protein structure and related models to therapeutic discovery, per official materials; an Alphabet company.

Who it serves

Pharmaceutical research programs and collaborators in AI-driven drug design.

Company background

United Kingdom

Product and AI capabilities

AI-first drug design company applying advances in protein structure and related models to therapeutic discovery, per official materials; an Alphabet company.

Key developments

Why it matters

Isomorphic Labs connects DeepMind-era protein modeling progress to commercial drug design under Alphabet.

Sector context

See Brel’s Healthcare sector hub for related profiles.

Sources and references

Official: https://www.isomorphiclabs.com

Sources and references

This article draws on publicly available company information, official websites, filings, interviews, announcements, and other cited sources. Information may change over time.

Company information is based on publicly available sources and is reviewed periodically. If you represent this company and would like to request a correction, contact Brel.

Explore Related Intelligence

The AI Brief

Weekly company intelligence in your inbox.

Subscribe